Study finds promising results for evinacumab in reducing triglyceride-rich lipoproteins

A post-hoc analysis of 3 clinical trials has provided promising evidence supporting the efficacy of evinacumab in reducing triglyceride-rich lipoproteins (TRLs) in patients with various lipid disorders. The analysis suggests that targeting TRL levels with evinacumab could be a potential future strategy for lipid-lowering therapies, with significant reductions observed across different patient cohorts.

The trials included patients with homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia, and severe hypertriglyceridemia. Evinacumab, administered either intravenously or subcutaneously at different doses and intervals, demonstrated significant reductions in TRL levels across all studies. Particularly noteworthy was the >50% reduction from baseline observed at the highest doses evaluated in patients with HoFH or refractory hypercholesterolemia.

The analysis also noted that at baseline, patients with severe hypertriglyceridemia entering one of the trials had higher TRL levels compared to other cohorts. However, the reductions in TRLs were consistent across all 3 trials, suggesting a potential benefit of evinacumab across different lipid disorders.

Importantly, the study found that evinacumab was generally well tolerated among patients, indicating its potential as a safe therapeutic option for lipid management.

Reference
Rosenson RS, Rader DJ, Ali S, et al. Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials. Cardiovasc Drugs Ther. 2024;doi: 10.1007/s10557-024-07567-z. Epub ahead of print. PMID: 38446275.